A call for open-source cost-effectiveness analysis

Date: August 29, 2017
Journal: Annals of Internal Medicine
Citation: Cohen JT, Neumann PJ, Wong JB

More Publications

Drugs cleared through the FDA’s expedited review offer greater gains than drugs approved by conventional process

View Publication

ICER’s revised value assessment framework for 2017–2019: A critique

View Publication

Implementation of medical Homes in federally qualified health centers

View Publication
View All Publications